id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2024-E-0440-0007,FDA,FDA-2024-E-0440,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2025-09-19T04:00:00Z,2025,9,2025-09-19T04:00:00Z,,2025-09-19T17:36:11Z,,0,0,09000064b8fb006c
FDA-2024-E-0440-0006,FDA,FDA-2024-E-0440,Determination of Regulatory Review Period for Purposes of Patent Extension; ROCTAVIAN,Notice,Determinations,2024-12-30T05:00:00Z,2024,12,2024-12-30T05:00:00Z,2025-03-01T04:59:59Z,2024-12-30T17:32:54Z,2024-31276,0,0,09000064868947c5
FDA-2024-E-0440-0005,FDA,FDA-2024-E-0440,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2024-12-27T05:00:00Z,2024,12,2024-12-27T05:00:00Z,,2024-12-27T14:14:09Z,,0,0,09000064868910a7
FDA-2024-E-0440-0004,FDA,FDA-2024-E-0440,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-07-29T04:00:00Z,2024,7,2024-07-29T04:00:00Z,,2024-07-29T16:06:49Z,,0,0,09000064865ffc83
FDA-2024-E-0440-0003,FDA,FDA-2024-E-0440,Letter to U.S. Patent and Trademark Office,Other,Letter(s),2024-04-26T04:00:00Z,2024,4,2024-04-26T04:00:00Z,,2024-04-26T13:33:52Z,,0,0,09000064864f2b50
FDA-2024-E-0440-0002,FDA,FDA-2024-E-0440,"Patent Term Extension Application for ROCTAVIAN® (valoctocogene roxaparvovec-rvox), Patent No. 9,504,762",Other,Application,2024-01-26T05:00:00Z,2024,1,2024-01-26T05:00:00Z,,2024-01-26T20:43:19Z,,0,0,09000064863b9ef9
FDA-2024-E-0440-0001,FDA,FDA-2024-E-0440,Letter from U. S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-01-26T05:00:00Z,2024,1,2024-01-26T05:00:00Z,,2024-01-26T20:43:13Z,,0,0,09000064863b9ef7